Eli Lilly’s stock on pace for record close as Crohn’s disease trial hits the mark
Up next
Author


Eli Lilly’s experimental Alzheimer’s drug donanemab on Monday moved a step closer to U.S. regulatory approval as it won support from an independent panel of advisers to the Food and Drug Administration.

You May Also Like
What 125 years of data says about diversification and investing at record highs

What 125 years of data says about diversification and investing at record highs

Global investment returns yearbook finds stock-market investing is profitable but volatile.
M&A activity falls as Wall Street clients tap the brakes on deals

M&A activity falls as Wall Street clients tap the brakes on deals

In the face of uncertainty around tariffs and other policy changes, companies…
Jimmy Kimmel has now returned to network TV. Other outspoken American workers may not be so fortunate.

Jimmy Kimmel has now returned to network TV. Other outspoken American workers may not be so fortunate.

Yes, your employer can fire you for your views on Charlie Kirk…

The amateur sleuths trying to crack real-life cold cases

Angela Watts arrived in the small Welsh village of Resolven, in the…